Drugs to treat high blood pressure reduce the risk of dementia 

Taking beta-blockers may help reduce the risk of dementia according to a new study. Dr. Lon White of the Pacific Health Research and Education Institute in Honolulu, Hawaii, USA, who will present the data during the 65th Annual Meeting of the American Academy of Neurology in San Diego in March, described the discovery as ‘fascinating’. He and his colleagues discovered the relationship between beta-blockers and dementia after studying 174 Japanese and U.S. elderly patients that were incorporated in the study of Honolulu-Asia Aging.

Postmortem studies revealed that all the 610 participants had hypertension or were receiving treatment of this disorder with medication. Among the 350 that had been treated, only 15% were taking a beta-blocker, 18% were prescribed a beta-blocker plus one or more different drugs and the others received other drugs for blood pressure treatment. While any type of blood pressure treatment was better than none, the researchers found that men who took beta blockers to treat only blood pressure had fewer brain abnormalities that were not treated but might have needed treatment had their hypertension received other drugs for treatment. 

The brains of participants who received beta-blockers showed a reduction in the number of brain abnormalities, including two types of brain injuries: those that indicate Alzheimer’s disease and micro bleeds. The men who had taken beta-blockers alone or in combination with another drug to treat blood pressure had significantly lower shrinkage in their brains. “As the number of people with Alzheimer’s disease will increase significantly as our population ages, it is increasingly important to identify factors that could delay or prevent the disease,” said Dr. White. “These results are very exciting, especially because beta blockers are a common treatment of hypertension.” 

Source: Medcenter.com, el portal médico líder de Latinoamérica

SOLACI.ORG

More articles by this author

AHA 2023 | SELECT Trial: Semaglutide in Patients Without Diabetes

Given the obesity pandemic projected for the year 2035, it is imperative to address this disease as a priority, through well-known hygienic-dietary measures and...

ACC 2023 | COORDINATE-DIABETES

Approximately only 2.7% of all diabetic patients with ischemic heart disease in the United States receive optimal treatment consisting in high doses of statins...

ACC 2023 | A DUE-Study (Phase III)

In pulmonary hypertension (PHT), 10 mg macitentan plus 40 mg tadalafil is recommended as a safe combination therapy for newly diagnosed patients or in a significant...

ACC 2023 | YELLOW III Study. Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease

Dr. Kini presented the results of the YELLOW III Study where she analyzed the effect of evolocumab on coronary plaque in patients with stable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...